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COMMENT
PATENTING THE FINGERPRINT OF GOD: HOW GENE
PATENTS VIOLATE THE PRODUCTS OF NATURE
DOCTRINE
Timothy M. Todd†
I. INTRODUCTION
Lisbeth Ceriani is a single mother with an eight-year-old daughter.1 In
May 2008, Lisbeth was diagnosed with stage IIA breast cancer.2 Due to
multiple tumors, she had a double mastectomy, along with chemotherapy
and radiation therapy.3 Lisbeth’s oncologists along with several genetic
counselors unanimously agree that she needs genetic testing. This genetic
test will determine whether she has genetic mutations in certain genes (the
BRCA genes) to help assess the risks for a potential surgery.4 Myriad
Genetics has such a genetic test.

† Managing Editor of Publication, LIBERTY UNIVERSITY LAW REVIEW, Volume 5. J.D.
Candidate (2011); Liberty University School of Law; M.S., B.S., Liberty University. I would
like to give all glory and honor to Jesus Christ my Lord and Savior. I would also like to
thank my beautiful wife, Regan, whose patience, love, and sacrifice has made this Comment
and my law school career possible—she is the epitome of Proverbs 31:10-31. Finally, thanks
to all those dedicated students on the Liberty University Law Review for their time and
effort, especially Mr. Andrew Connors, whose direction and insight were invaluable.
1. Brendan L. Smith, Wrangling Genes: As the Law Changes and New Medical
Frontiers Open, the Dispute Over Genetic Patents Intensifies, A.B.A. J., Jul. 2009, at 56, 57,
59.
2. BRCA-Plaintiff Statements, ACLU (May 12, 2009), http://www.aclu.org/freespeech_womens-rights/brca-plaintiff-statements#ceriani. Stage IIA breast cancer is when:
[N]o tumor is found in the breast, but cancer is found in the axillary lymph
nodes (lymph nodes under the arm); or the tumor is 2 centimeters or smaller
and has spread to the axillary lymph nodes; or the tumor is larger than 2
centimeters but not larger than 5 centimeters and has not spread to the axillary
lymph nodes.
Stages of Breast Cancer, NATIONAL CANCER INSTITUTE, (Sept. 09, 2010), http://www.cancer.
gov/cancertopics/pdq/treatment/breast/Patient/page2#Keypoint11.
3. ACLU, supra note 2.
4. Id. A mutation in the BRCA1 gene indicates an increased risk for breast and ovarian
cancer. See Low-Penetrance Predisposition to Breast and Ovarian Cancer, NATIONAL
CANCER INSTITUTE (Oct. 08, 2010), http://www.cancer.gov/cancertopics/pdq/genetics/breastand-ovarian/HealthProfessional/page3.

78

LIBERTY UNIVERSITY LAW REVIEW

[Vol. 5:77

Lisbeth’s insurance company fully covers Myriad Genetics’s BRCA
genetic testing but only if performed by a contracted provider.5 The
problem, however, is that there is only one lab in the country that performs
this particular genetic test—Myriad’s own lab in Utah.6 Myriad has refused
to contract with Lisbeth’s insurance for the genetic testing.7 There are no
other alternatives for Lisbeth, or similarly situated patients, because Myriad
holds patents on the underlying human BRCA genes.8 Therefore, no other
laboratory, company, university, or even non-profit entity can use the genes
to develop alternative and better tests, or to create cures that use these
genes.
Thousands of human genes have been patented.9 Patented genes range
from those with little utility to those that have vital utility—for instance, the
ability to detect a predisposition toward breast cancer.10 Since patent
holders have the right to preclude others from using their “inventions,” the
patenting of genes has stymied research, restricted access to medical tests,
and granted monopolies to the building blocks of life.11 This Comment
addresses the patenting of human genes and focuses on the BRCA1 and
BRCA2 genes, which are invaluable in breast cancer research and
detection.12 The BRCA1 and BRCA2 genes are patented by Myriad
Genetics.13 Thus, Myriad may prevent others from using the genes in a
manner covered by the claims of the patent.14 This preventative ability
means that Myriad, or its lucky licensees, are the only individuals who can
use these genes in developing medical tests to detect breast cancer and to
research a potential cure. This problem, however, is not limited to Myriad
and breast cancer. There are gene patents that cover a multitude of
5. ACLU, supra note 2.
6. Id.
7. Id.
8. Myriad holds patents on the “purified and isolated forms” of the BRCA1 and
BRCA2 genes. U.S. Patent No. 5,837,492 (filed Apr. 29, 1996) (patent on isolated BRCA2
DNA); U.S. Patent No. 5,747,282 (filed June 7, 1995) (patent on isolated BRCA1 DNA).
9. John F. Merz & Mildred K. Cho, What Are Gene Patents and Why Are People
Worried About Them?, 8 COMMUNITY GENETICS 203 (2005).
10. E.g., U.S. Patent No. 5,837,492 (filed Apr. 29, 1996) (patent on isolated BRCA2
DNA); U.S. Patent No. 5,747,282 (filed June 7, 1995) (patent on isolated BRCA1 DNA).
11. See infra Part III.D (discussing how patents on human genes stymie research).
12. See supra note 10.
13. Id.
14. 35 U.S.C. § 271 (2010); see Rebecca S. Eisenberg, Patents and the Progress of
Science: Exclusive Rights and Experimental Use, 56 U. CHI. L. REV. 1017, 1021 (1989).
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diseases.15 Thus, scientists, researchers, and medical professionals are
limited in their research and treatment of these diseases because of patented
human genes.16
The Founders gave the federal government the power to grant patents
because they recognized that the public could ultimately benefit from
limited monopolies.17 They realized that without patent protection, an
inventor might not reveal his discovery to the public, but with the promise
of a time-constrained monopoly, that calculus changes.18 Instead, the
inventor will unleash his or her genius to the public, and then the public
will have use of the invention after the patent expires.19 Hence, the United
States Supreme Court has explained that to receive a patent an invention
must be “a product of human ingenuity,” thus excluding anything that
occurs naturally from patent eligibility.20 This is known as the “products of
nature” doctrine.
In its current form, the patenting of human genes tramples on the
venerable “products of nature” doctrine. Because of the United States
Patent and Trademark Office’s (PTO) misapplication of the products of
nature doctrine, research has slowed and human life devalued,21 among
other consequences.22 The current gene patent framework posits that human
genes23 are patentable so long as the gene is “purified and isolated” and the

15. These patents cover genes associated with other diseases such as Alzheimer's
disease, asthma, hemochromatosis, forms of colon cancer, and Canavan disease, BRCA:
Genes and Patents, ACLU (May 27, 2009), http://www.aclu.org/freespeech/gen/
39556res20090512.html#04.
16. See infra Part III.D.
17. See U.S. CONST. art. I, § 8, cl. 8.
18. Beth E. Arnold & Eva Ogielska-Zei, Patenting Genes and Genetic Research Tools:
Good or Bad for Innovation?, 3 ANN. REV. GENOMICS & HUM. GENETICS 415, 416 (2002).
19. Id.
20. Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980).
21. Ownership of human genes infringes upon human dignity because it commercializes
body parts. It is equivalent to human ownership, and it cheapens that which defines “human
identity.” Mark J. Hanson, Religious Voices in Biotechnology: The Case of Gene Patenting,
in CLAIMING POWER OVER LIFE 94 (Mark J. Hanson ed., 2001) (citing Baruch A. Brody,
Protecting Human Dignity and the Patenting of Human Genes, in PERSPECTIVES ON GENETIC
PATENTING: RELIGION, SCIENCE, AND INDUSTRY IN DIALOGUE 111-26 (Audrey R. Chapman
ed., 1999)).
22. See infra Part III.
23. The PTO applies this standard to all genes. See infra Part III.C.

80

LIBERTY UNIVERSITY LAW REVIEW

[Vol. 5:77

utility of the gene is known.24 This framework wildly misconstrues and
implicitly rejects the products of nature doctrine.
Therefore, there needs to be a new framework dealing mostly with utility
to restore the products of nature doctrine, to treat life with the sanctity it
deserves, and to minimize the harsh effects that human gene patents have
had on medical research and treatment. This Comment proposes a twopronged approach to revising the gene patent utility standards: (1) the
claimed utility cannot be substantially similar to the utility found in the
naturally occurring gene, and (2) that the inventor needs actually to imbue
the utility in the gene (i.e., the utility is not due to a natural mutation, or
other natural trait, but rather the genius of the inventor). Although this
framework is proposed for gene patents, it should also be applied to the
gamut of chemical and biological patents to harmonize our current scheme
of patent law with its overall purpose of encouraging innovation, while
keeping naturally occurring phenomenon in the storehouse of all men.25
This Comment’s two-pronged test is needed to: (1) restore the products of
nature doctrine; (2) keep important biological information in the storehouse
of all men; and (3) respect the sanctity of human life.
This Comment starts with a patent primer, including the constitutional
and statutory framework. Next, the Comment introduces the products of
nature doctrine and its foundation in American jurisprudence. The
Comment then discusses the biological foundation needed to scrutinize
gene patents. The Comment addresses the problem presented by the
patenting of naturally occurring human genes in a “purified and isolated”
form, in particular the BRCA1 and BRCA2 genes. Finally, this Comment
proposes that (1) the Patent and Trademark Office should change its utility
guidelines, (2) Congress should pass ethics regulations precluding human
gene patents, and (3) courts confronted with the validity of human gene
patents should apply the proffered rule, likely striking down most gene
patents covering purified and isolated forms of naturally occurring human
genes.26

24. See infra Part III.C (discussing the current utility standard).
25. Thomas Jefferson was a staunch proponent of sharing knowledge. He thought it was
a “sure foundation . . . for the preservation of freedom and happiness.” Thus, those things of
nature, which are the foundation of all other discoveries, Jefferson considered public
property. See JEFFREY H. MATSUURA, JEFFERSON VS. THE PATENT TROLLS 37-38, 41 (2008).
26. This Comment also asserts that the “march in” rights of the Bayh-Dole Act are
inadequate as a solution for publicly funded gene patent research. See infra Part IV.E.
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II. BACKGROUND
A. The Constitutional & Historical Background of Patent Protection
The Constitution grants Congress the power to “promote the Progress of
Science and useful Arts by securing for limited Times to Authors and
Inventors the exclusive Right to their respective Writings and
Discoveries.”27 Under this authority, Congress passed the first patent Act in
1790.28 The Act created a three-member board of commissioners comprised
of the Secretary of State, Secretary of War, and the Attorney General.29 The
board had the sole discretion to grant a patent.30 Under the Act, the board
issued a patent if the invention was “sufficiently useful and important.”31
This statutory scheme proved to be too cumbersome;32 thus, Congress
enacted the Patent Act of 1793.33 This Act created the registration system,34
which is still essentially in use today. Under the Act, only the Secretary of
State had the authority to grant patents.35 In addition, the Act required the
State Department to maintain a registry of patents.36 The registration
system, however, did not establish patent validity; that question was left to
the courts.37 Congress went through two more iterations of patent statutes38
before arriving at the current 1952 Act.39

27. U.S. CONST. art. 1, § 8, cl. 8.
28. ROGER SCHECHTER & JOHN THOMAS, PRINCIPLES OF PATENT LAW 16 (2d ed. 2004);
see Act of Apr. 10, 1790, ch. 7, 1 Stat. 109 (1790) (repealed 1793).
29. SCHECHTER & THOMAS, supra note 28.
30. Act of Apr. 10, 1790, ch. 7, 1 Stat. at 109-10.
31. Id. at 110.
32. The examination process, coupled with their other government duties, proved to be
too onerous for the three-member board. See SCHECHTER & THOMAS, supra note 28.
33. Act of Feb. 21, 1793, ch. 11, 1 Stat. 318 (1793) (repealed 1836).
34. The registration system refers to the process of applying for and registering a patent
with the U.S. Patent and Trademark Office. It is only through this registration process that
patent protection is recognized.
35. Act of Feb. 21, 1793, ch.11, 1 Stat. at 320 (1793).
36. Id. at 321.
37. SCHECHTER & THOMAS, supra note 28.
38. See Act of July 4, 1836, ch. 357, 5 Stat. 117 (1836) (amended 1879) (repealed
1952).
39. Act of July 19, 1952, ch. 950, 66 Stat. 792 (1952) (codified as amended in 35 U.S.C.
§ 1).

82

LIBERTY UNIVERSITY LAW REVIEW

[Vol. 5:77

Patent protection is not an American creation; rather, intellectual
property protection traces back to Roman law.40 Moreover, in England, the
Crown granted a “royal patent of privilege” for fourteen years to the
inventor of a new manufacture or product.41 Not all of the Founders,
however, were enthusiastic about the national government affording
intellectual property protection. Thomas Jefferson, a member of the patent
board for several years, disfavored granting patent protection.42 Jefferson’s
view on patent protection is important to understand because it underlines
the impetus behind the products of nature doctrine. Jefferson believed that
“ideas should freely spread from one to another over the globe, for the
moral and mutual instruction of man, and improvement of his condition.”43
Jefferson was averse to monopolies.44 Thus, Jefferson advocated a high
standard of patentability.45 Jefferson also realized the difference between
basic and applied science.46 The elements of “basic” science, or the
structure and operation of natural forces, are to be protected from
patentability because of what is now called the products of nature doctrine.
In contrast, applied science, which is the useful application of basic science,
is to be the proper subject matter of patents.47 Jefferson’s view is crucial to
remember because, as he suggested, overly broad patent protection could
stymie development.48
B. The Statutory Requirements to Receive a Patent
Patents come into existence only via a grant from the government.49 The
United States Patent and Trademark Office, an agency within the U.S.
Department of Commerce, is charged with evaluating patent applications.50

40. See 2 WILLIAM BLACKSTONE, COMMENTARIES *406 (alluding to a form of copyright
protection in ancient Rome).
41. Id. at 408.
42. Letter from Thomas Jefferson to Isaac McPherson (Aug. 13, 1813), reprinted in 3
THE FOUNDERS’ CONSTITUTION 42, 42-43 (Philip B. Kurland & Ralph Lerner eds., 1987).
43. Id. at 42.
44. Graham v. John Deere Co., 383 U.S. 1, 7 (1966).
45. Id. at 9.
46. See MATSUURA, supra note 25, at 81.
47. Id. at 81-82.
48. See id.
49. SCHECHTER & THOMAS, supra note 28, at 221.
50. Id.
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Thus, the PTO first examines whether a patent application meets the
statutory requirements.
Under the current statutory framework, there are five requirements for
patentability: proper subject matter,51 utility,52 novelty,53 non-obviousness,54
and sufficient definition.55
1. Proper Subject Matter
An inventor can obtain a patent only if his invention fits within a
statutorily approved category, as set forth in 35 U.S.C § 101.56 Generally,
patentable subject matter can be described as either a product or a process.57
Product claims cover tangible things.58 Thus, product inventions can be
machines, manufactures, or compositions of matter.59 Compositions of
matter include chemical compounds, mixtures, and alloys.60 Therefore,
gene patents are product patents. Product patents are described in terms of
their structural elements.61 Process patents, on the other hand, “involve a
series of acts performed in order to produce a given result.”62 Process
patents are described by a list of steps.63 While gene patents are normally
product patents, there are gene-based process patents that cover the process
to reproduce the gene, and earlier gene patents may cover the actual process
used to discover the gene.64 The United States Supreme Court has held that
patentable subject includes “anything under the sun that is made by man.”65
51. See 35 U.S.C. § 101 (2006).
52. See id.; Brenner v. Manson, 383 U.S. 519, 534-35 (1966); DONALD S. CHISUM,
CHISUM ON PATENTS § 4.01 (1997); 69 C.J.S. Patents § 59.
53. See 35 U.S.C. § 102(a)–(b) (2006); Bonito Boats, Inc. v. Thunder Craft Boats, Inc.,
489 U.S. 141, 149-50 (1989).
54. See 35 U.S.C. § 103(a) (2006); Graham v. John Deere Co., 383 U.S. 1, 11 (1966).
55. 35 U.S.C. § 112 (2006).
56. 35 U.S.C. § 101 (2006).
57. JOHN R. THOMAS, PHARMACEUTICAL PATENT LAW 30 (2005).
58. Id.
59. See 35 U.S.C. § 101.
60. THOMAS, supra note 57.
61. Id. at 31.
62. Id.
63. Id.
64. See, e.g., U.S. Patent No. 5,837,492 (filed Apr. 29, 1996) (patent on isolated
BRCA2 DNA); U.S. Patent No. 5,747,282 (filed June 7, 1995) (patent on isolated BRCA1
DNA).
65. Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980).
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But historically, proper subject matter did not include anything made by
man that also existed in nature.66
2. Utility
The concept of utility, or usefulness, is inherent in the concept of
promoting the “Progress of . . . Useful Arts.”67 Furthermore, utility is
required by statute.68 An invention is useful if it provides some identifiable
benefit.69 To be useful, an invention must also be operable; meaning it must
be “capable of being used to effect the object proposed.”70 Utility is a
relatively low threshold; a patent will be invalid for lack of utility only
when it is “totally incapable of achieving a useful result.”71 Another facet of
utility is “practical utility.” Practical utility requires that the invention
provide some benefit to the public.72 The utility requirement is paramount
in biotechnology patents. As the United States Supreme Court has
explained, the inventor must know the specific utility of a chemical
compound (i.e., what the compound actually does) to patent it.73
3. Novelty
To be patentable, the invention must be novel; meaning it must be new.74
Accordingly, the invention “must not have been previously known.”75 This
requires that the invention’s essence has not been disclosed in prior art.76 A
corollary of the novelty principle is “anticipation.”77 Anticipation mitigates
novelty when the prior art discloses all the elements of the patent, or their
functional equivalents.78
66. See infra Part II.D.
67. Graham v. John Deere Co., 383 U.S. 1, 6 (1966).
68. See 35 U.S.C. § 101 (2006) (granting a patent only to an inventor that “invents or
discovers any . . . useful process”).
69. Juicy Whip, Inc. v. Orange Bang, Inc., 185 F.3d 1364, 1365 (Fed. Cir. 1999).
70. Mitchell v. Tilghman, 86 U.S. (19 Wall.) 287, 396 (1873).
71. See Brooktree Corp. v. Advanced Micro Devices, Inc., 977 F.2d 1555, 1571 (Fed.
Cir. 1992).
72. Nelson v. Bowler, 626 F.2d 853, 856 (C.C.P.A. 1980).
73. Brenner v. Manson, 383 U.S. 519, 534-35 (1966).
74. See 35 U.S.C. § 102(a) (2006); C.R. Bard, Inc. v. M3 Systems, Inc., 157 F.3d 1340,
1349 (Fed. Cir. 1998).
75. C.R. Bard, Inc., 157 F.3d at 1349.
76. Roberts v. Sears, Roebuck & Co., 723 F.2d 1324, 1332 (7th Cir. 1983).
77. See 69 C.J.S. Patents § 30 (2010).
78. Armco, Inc. v. Republic Steel Co., 707 F.2d 886, 889 (6th Cir. 1983).
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4. Nonobviousness
A patent cannot be issued if the invention was obvious.79 Thus, an
invention is unpatentable if at the time the invention was made, it would
have been “obvious” to a person having ordinary skill in the art or technical
field;80 this is judged in light of the prior art. The invention must be
considered as a whole and the claims in their entirety. 81 Obviousness
cannot be based upon hindsight.82
In Graham v. John Deere Co., the United States Supreme Court
solidified its position that the patented claims must be the work of an
inventor, not a skillful mechanic.83 Thus, although something may be a new
invention in the sense it has not been created before, it may nevertheless be
unpatentable because the difference between the prior art and the new thing
is not sufficient to warrant patent protection.84 The Graham Court laid out
three factual inquiries to be determined under an obviousness analysis: (1)
the scope and content of the prior art; (2) the differences between the prior
art and the instant claims; and (3) the level of ordinary skill in the pertinent
art.85 For example, the obviousness requirement, especially under Graham,
is to preclude the patent protection of a hair comb made of ivory instead of
being made of plastic.86
More recently in KSR International Co. v. Teleflex Inc.,87 the Supreme
Court further clarified the obviousness requirements under § 103. In KSR,
the Court held that if a patent is merely a combination of prior art, with no
drastic change in its respective function, it is obvious if an ordinary person
trained in the field would have combined the articles.88 Under the KSR
framework, if there is a known problem in the field and there are a finite
79. See 35 U.S.C. § 103(a) (2006); Milgo Elec. Corp. v. United Bus. Commc’ns, Inc.,
623 F.2d 645, 654 (10th Cir. 1980).
80. 35 U.S.C. § 103(a).
81. Kahn v. Gen. Motors Corp., 135 F.3d 1472, 1479-80 (Fed. Cir. 1998).
82. Id. at 1479.
83. Graham v. John Deere Co., 383 U.S. 1, 11 (1966); Hotchkiss v. Greenwood, 52 U.S.
(11 How.) 248, 267 (1851) (affirming that a patent was invalid because “there was an
absence of that degree of skill and ingenuity which constitute essential elements of every
invention. In other words, the improvement is the work of the skilful mechanic, not that of
the inventor”).
84. Graham, 383 U.S. at 14.
85. Id. at 17
86. See id. at 10 n.3.
87. KSR Int’l Co. v. Teleflex Inc., 550 U.S. 398 (2007).
88. Id. at 420.
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number of possible solutions, then an ordinary person in the field would try
these possible solutions; thus, the resulting “invention” is not due to
innovation but rather ordinary skill and common sense.89
5. Definability
Finally, a patent application must contain a written description in “full,
clear, concise, and exact terms” to allow another person to make and use
the invention.90 The purpose of this requirement is to allow the public to use
the invention after the patent expires.91
C. Patent Examination Process
A patent application, or the patent instrument, must contain a
“specification” that explains the invention.92 The PTO has promulgated
regulations concerning the contents of the specification.93 The specification
contains, inter alia, a title, an abstract, a detailed description, and even
drawings.94 Once an inventor completes a patent application, it is sent to the
PTO.95 Once received by the PTO, the application is assigned an
examiner.96 The examiner evaluates the prior art regarding the claims.97
After evaluating the prior art, the examiner will determine whether the
application has met the statutory requirements.98 If the examiner finds that
the application meets the statutory requirements, the examiner will issue the
patent; however, if the statutory requirements are lacking, the examiner will
send a denial notice informing the applicant that the patent is denied.99
Upon receipt of such a notice, the applicant can avail himself of the PTO’s
administrative procedures and ultimately the courts.100

89.
90.
91.
92.
93.
94.
95.
96.
97.
98.
99.
100.

Id. at 421.
35 U.S.C. § 112 (2006).
Schriber-Schroth Co. v. Cleveland Trust Co., 305 U.S. 47, 57 (1938).
See 35 U.S.C. § 112.
See 37 C.F.R. § 1.77 (2009).
SCHECHTER & THOMAS, supra note 28, at 183.
Id. at 225.
Id.
Id.
Id. at 225-26.
Id. at 226.
Id.
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D. The Products of Nature Doctrine
The “products of nature doctrine” holds that an invention
indistinguishable from something occurring in nature is not patentable.101
The products of nature doctrine appears as early as the late nineteenth
century.102 A prime example of the doctrine’s early application is Ex parte
Latimer.103 Latimer applied for two patents: one for his process and one for
his product. The Patent Commissioner denied a patent to Latimer’s woven
fabric consisting of cellular tissues of the Pinus Australis plant.104 Latimer
spun and wove the plant filaments making a fiber.105 The patent examiner
denied the patent because the claim did not “set forth any physical
characteristics by which the fiber can be distinguished from other vegetable
fibers.”106 The Patent Commissioner held that nature imbued the fiber with
its characteristics, not any novel input or genius by Latimer.107
The modern degradation of the products of nature doctrine spawns from
the misinterpretation of Diamond v. Chakrabarty.108 Chakrabarty was a
microbiologist for General Electric.109 Chakrabarty’s patent application
asserted thirty-six claims concerning ‘“a bacterium from the genus
Pseudomonas containing therein at least two stable energy-generating
plasmids, each of said plasmids providing a separate hydrocarbon
110
degradative pathway.”’ Essentially, Chakrabarty invented a human-made
genetically-engineered bacterium capable of breaking down crude oil.111
This bacterium was neither found in nature, nor was this particular property
112
Thus, Chakrabarty
exhibited in any naturally occurring bacteria.

101. See Parker v. Flook, 437 U.S. 584, 589 (1978); Funk Bros. Seed Co. v. Kalo
Inoculant Co., 333 U.S. 127, 130 (1948).
102. See Ex parte Latimer, 1889 Dec. Comm’r Pat. 123, 123 (1889).
103. Id.
104. Id.
105. Id.
106. Id. at 124.
107. Id. at 125.
108. Diamond v. Chakrabarty, 447 U.S. 303 (1980).
109. Id. at 305.
110. Id.
111. Id.
112. Id.
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engineered a unique bacterium possessing significant value for treating oil
113
spills.
The patent examiner denied Chakrabarty’s claims on the grounds “(1)
that micro-organisms are ‘products of nature,’ and (2) that as living things
they are not patentable subject matter under 35 U.S.C. § 101.”114 The
Patent Office Board of Appeals affirmed the examiner’s decision and
concluded that § 101 was not intended to cover living things, including
laboratory-created micro-organisms.115
The Supreme Court reversed and held that Chakrabarty’s bacterium
satisfied the requirements of § 101.116 According to the Court, the issue was
whether micro-organisms were patentable subject matter.117 The Court held
that “anything under the sun that is made by man” is patentable subject
matter.118 The Court reasoned that Congress wanted the patent statutes to be
given a wide scope, and therefore Chakrabarty’s bacterium was not a
product of nature.119
E. A Basic Biological Background
Since this Comment argues against the current practice of patenting
human gene sequences, a proper foundation of genetics is appropriate.
Every human cell contains forty-six chromosomes.120 Each of these
chromosomes contains a single deoxyribonucleic acid (“DNA”) molecule
along with various proteins.121 Every living organism possesses the
information to “copy” itself.122 This ability supports the hereditary function,
or the passing of genetic information from itself to offspring.123 Therefore,
DNA is the material of heredity.124 DNA is made of smaller units called

113. Id. at 305 & n.2 (noting that Chakrabarty’s bacterium promised more efficient and
rapid oil-spill control).
114. Id. at 306.
115. Id.
116. Id. at 318.
117. Id. at 307.
118. Id. at 309.
119. Id. at 308.
120. STEVE BOLSOVER ET AL., FROM GENES TO CELLS 75 (1997).
121. Id. at 79.
122. RICHARD J. REECE, ANALYSIS OF GENES AND GENOMES 1 (2004).
123. See id. at 2.
124. Id. at 7.
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nucleotides;125 thus, DNA is a polynucleotide.126 DNA has four nucleotides:
adenine (A), guanine (G), thymine (T), and cytosine (C).127 The “genetic
information” is the combination and order of these nucleotides.128 DNA is a
double-stranded molecule, forming a double helix, joined by hydrogen
bonds.129 DNA molecules can be very large; for example, the chromosome
of E. Coli (a bacteria) comprises two DNA strands, each containing
approximately 4.5 million nucleotides.130 DNA plays an integral part in
“coding” and “decoding” genetic information.131 The information in the
DNA (i.e., the order of the nucleotides) is transferred to its “daughter” by
“replication.”132 Replication occurs when the cell divides.133 During
replication, the double helix unwinds and serves as a template for
replication.134 DNA directs the creation of proteins with the help of
ribonucleic acid (“RNA”).135 The DNA transfers its code to the RNA, a
process known as transcription.136 The RNA is translated into amino
acids.137 This is the basic process wherein cells divide and form the building
blocks of life. This process is used to create proteins, the body’s main
building blocks.138
F. Basic Gene Biology
The exact definition of a “gene” has bewildered scientists.139 Early
definitions of genes were used to describe a “unit of inheritance of an

125. JAMES N. THOMPSON ET AL., PRIMER OF GENETIC ANALYSIS: A PROBLEMS APPROACH
1 (2d ed. 1997).
126. NORMAN MACLEAN, GENES AND GENE REGULATION 4 (1989).
127. THOMPSON ET AL., supra note 125.
128. See BOLSOVER ET AL., supra note 120, at 79.
129. MACLEAN, supra note 126, at 4.
130. BOLSOVER ET AL., supra note 120.
131. THOMPSON ET AL., supra note 125, at 16.
132. BOLSOVER ET AL., supra note 120, at 79.
133. Id. at 133.
134. Id.
135. Id. at 79.
136. Id.
137. Id.
138. How Genes Work, NAT’L INST. OF GEN. MED. SCIS., (2006), http://publications.
nigms.nih.gov/thenewgenetics/chapter1.html (last updated Apr. 2010).
139. JEREMY DALE & MALCOM VON SCHANTZ, FROM GENES TO GENOMES: CONCEPTS AND
APPLICATIONS OF DNA TECHNOLOGY 15-16 (2d ed. 2007).
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observable characteristic,” known as a “phenotype.”140 As the science of
genetics progressed, so did the nomenclature; genes were later defined as a
DNA sequence coding for a specific polypeptide.141 This definition,
however, ignores certain gene types that are used for certain RNA
molecules.142
In modern science, a “gene” is a “sequence of DNA [deoxyribonucleic
acid] that carries the code for a protein or RNA [ribonucleic acid] molecule,
and frequently includes regulatory regions at either or both ends.”143
Basically, genes are a unique part of a chromosome that determine a
particular characteristic.144
III. THE GENE PATENT PROBLEM
Unfortunately, the PTO has ignored the products of nature doctrine and
has been issuing thousands of patents encompassing human gene sequences
that are effectively the same as those existing naturally in the body.
Patenting genes has many troubling consequences, namely, slowing
research and devaluing human life.145 Concerning human gene patents in
particular, Dr. John E. Sulston, the 2002 Nobel Laureate in Medicine,
contends that human gene patents have slowed the rate of medical and
scientific advancement.146
In the early 1990s, large amounts of money, both in public and private
funds, were invested in biotechnology and genetic research.147 The public
funds expended on the Human Genome Project alone are estimated at more
than $3 billion dollars.148 The biotechnology sector invested $15.6 billion
dollars in research and development in 2001.149 A 2005 study found that
4,382 of the nearly 24,000 human genes have express intellectual property
140. Id. at 15; see MACLEAN, supra note 126, at 1 (noting that the first use of “gene” was
used to describe Mendel’s observations on peas).
141. DALE & VON SCHANTZ, supra note 139, at 15.
142. Id.
143. MACLEAN, supra note 126, at 3.
144. REECE, supra note 122, at 40.
145. The PTO, however, contends that gene patents do not inhibit the rate of research.
See Utility Examination Guidelines, 66 Fed. Reg. 1092, 1094 (Jan. 5, 2001).
146. See John Sulston, Beyond Release: The Equitable Use of Genomic Information, 362
THE LANCET 400, 400-02 (2003).
147. Bryn Williams-Jones, History of a Gene Patent: Tracing the Development and
Application of Commercial BRCA Testing, 10 HEALTH L. J. 123, 124 (2002).
148. Id.
149. Id.
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claims.150 Thus, roughly twenty percent of the human genome has been
patented,151 including genes associated with an array of diseases such as
Alzheimer’s disease, asthma, hemochromatosis, forms of colon cancer, and
Canavan disease.152 Even U.S. government agencies, such as the National
Institutes of Health, have sought patent protection for human genes.153
Thousands of human genes have been patented in the United States.154
Currently, “isolated”155 full-length genes are patentable in the United
States.156 A gene patent owner possesses a negative right that enables him
or her to enjoin others from using the gene sequence without the patent
holder’s permission.157 This ability to prevent and enjoin arises in research
and medical venues when researchers cannot utilize a particular gene
sequence because the isolated and purified form of the gene has been
patented.158 In patent law, a gene is treated as a normal chemical
compound,159 despite performing dual roles as a physical substance and a

150. BRCA: Genes & Patents, ACLU, (May 27, 2009), http://www.aclu.org/freespeech/brca-genes-and-patents#_ftnref2. (citing Kyle Jensen & Fiona Murray, Intellectual
Property Landscape of the Human Genome, 310 SCIENCE 239, 239-40 (2005)).
151. The economic incentive to patent a human gene is staggering. For example, the
holder of a patent relating to Down syndrome estimates his royalties to be at least over $100
million for the term of the patent. See Jon F. Merz, Disease Gene Patents: Overcoming
Unethical Constraints on Clinical Laboratory Medicine, 45 CLINICAL CHEMISTRY 324, 324
(1999).
152. BRCA: Genes & Patents, ACLU (May 27, 2009), http://www.aclu.org/freespeech/
gen/39556res20090512.html#04.
153. In 1995, the National Institutes of Health (NIH) received a patent on a cell line
originating from a member of the Hagahai tribe in Papua New Guinea. U.S. Patent No.
5,397,696 (filed Aug. 12, 1991). The NIH posited that the cell line could be used to make
vaccines for T-cell leukemia; but, the NIH abandoned the patent because of international
outcry alleging this amounted to “genetic theft.” See Lindsey Singeo, The Patentability of
the Native Hawaiian Genome, 33 AM. J.L. & MED. 119, 124 (2007).
154. John F. Merz & Mildred K. Cho, What Are Gene Patents and Why Are People
Worried About Them?, 8 COMMUNITY GENETICS 203, 203 (2005).
155. See infra note 199.
156. See Beth E. Arnold & Eva Ogielska-Zei, Patenting Genes and Genetic Research
Tools: Good or Bad for Innovation?, 3 ANN. REV. GENOMICS & HUM. GENETICS 415, 420
(2002).
157. Merz & Cho, supra note 154, at 204.
158. See infra note 212.
159. Amgen v. Chugai Pharm. Co., 927 F.2d 1200, 1206 (Fed. Cir. 1991) (“A gene is a
chemical compound, albeit a complex one.”).
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biological database.160 Thus, gene patents are actually patents on certain
DNA sequences, including their inherent biological databases.161 A gene
patent’s claim will actually list out the nucleotides that compose the gene,
at least in its “purified and isolated form.”162
A. Myriad’s Patent on the Breast Cancer Gene
Breast cancer is a common non-skin cancer affecting vast numbers of
women and even men.163 Treatment options for breast cancer depend on
multiple factors including the type, size, and location of the cancer within
the breast.164 Some women who are diagnosed with breast cancer have
inherited particular genes associated with increased risk of developing the
cancer—the BRCA1 and BRCA2 genes.165 The BRCA1 and BRCA2 genes
have been “strongly associated with hereditary breast cancer.”166 Mutations
in the BRCA1 gene are also associated with “cervical, uterine, pancreatic,
and colon cancer . . . .”167 In men, BRCA1 mutations are associated with
male breast cancer, pancreatic cancer, and testicular cancer.168 The BRCA1
gene is on chromosome seventeen with 5,592 base pairs that code for a
protein of 1,863 amino acids.169 This protein is critical for DNA repairing
and other functions; thus, when the gene is altered due to a mutation, it

160. Roger D. Klein, Gene Patents and Genetic Testing in the United States, 25 NATURE
BIOTECHNOLOGY 989, 990 (2007); see also Amgen, 927 F.2d at 1206. There are also other
concerns surrounding the significance of what is a “gene.” For example, if it is merely a
chemical, then arguably it should not receive special treatment; however, if a human gene is
more ethically significant, then a more heightened standard is warranted. See infra Part
IV.C; see also Mark J. Hanson, Religious Voices in Biotechnology: The Case of Gene
Patenting, in CLAIMING POWER OVER LIFE: RELIGION AND BIOTECHNOLOGY POLICY 72 (Mark
J. Hanson ed., 2001) (exploring how framing the significance of a gene can affect the policy
debate).
161. David Resnik, Are DNA Patents Bad for Medicine?, 65 HEALTH POL’Y 181, 183
(2003).
162. See U.S. Patent No. 5,747,282 fig.10A (filed June 7, 1995).
163. Williams-Jones, supra note 147, at 127.
164. Id.
165. Id.
166. Id.
167. BRCA 1 and BRCA 2: Cancer Risk and Genetic Testing, NATIONAL CANCER
INSTITUTE (last updated May 29, 2009), http://www.cancer.gov/cancertopics/factsheet/Risk/
BRCA#a2.
168. Id.
169. Williams-Jones, supra note 147, at 127.
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leads to abnormal cellular gene expression.170 The BRCA2 gene is located
on chromosome thirteen and is even larger with 10,254 base pairs that code
for a protein of 3,418 amino acids.171 The functions of the BRCA2 gene are
similar to the BRCA1 gene, except that BRCA2 tumors and mutations
exhibit different cellular expression.172 Individuals with the requisite
BRCA1 and BRCA2 mutations are estimated to have a lifetime risk of forty
to eighty-five percent for developing breast cancer, and sixteen to forty
percent for developing ovarian cancer.173 The children of parents with
BRCA mutations have a fifty percent chance of inheriting the gene
mutation.174
Myriad Genetics (Myriad), a Salt Lake City based biopharmaceutical
company, has patents on both the BRCA1 and BRCA2 genes.175 In addition
to the BRCA genes,176 Myriad has been involved in discovering other
disease susceptibility genes177 and developing tests to exploit those genetic
mutations.178 Due to its patent, Myriad has also developed a genetic test that
uses the BRCA genes to detect their presence.179 The BRCA test consists of
three subtests that can be used depending on the medical situation.180

170. Id.
171. Id.
172. Id.
173. Id. at 128.
174. Id.
175. U.S. Patent No. 5,837,492 (filed Apr. 29, 1996) (patent on isolated BRCA2 DNA);
U.S. Patent No. 5,747,282 (filed June 7, 1995) (patent on isolated BRCA1 DNA).
176. Interestingly, the Mormon Church has amassed one of the world’s most extensive
genealogical databases. Myriad was able access this data, which helped it to identify the
BRCA1 gene. See PHILLIP W. GRUBB, PATENTS FOR CHEMICALS, PHARMACEUTICALS, AND
BIOTECHNOLOGY 302 (5th ed. 2010).
177. Disease gene patents “claim the observation of an individual’s genetic makeup at a
disease-associated locus when done for the purpose of diagnosis.” Merz, supra note 151. A
study found that diagnostic type patents to be the most prevalent type of gene sequence
patents. Id.
178. Williams-Jones, supra note 147, at 130. For example, Myriad also has genetic tests
for hereditary non-polyposis colorectal cancer, cardiovascular disease, and melanoma, and
has a test in development for prostate cancer. Id.
179. Id. at 133. Myriad also has patents on the testing applications of this gene, as
exemplified in the ACLU lawsuit.
180. Id. at 133-34. The “Single site BRACAnalysis” is approximately $250; “Multisite 3
BRACAnalysis” is approximately $450; and the “Comprehensive BRACAnalysis” is
approximately $2,600 (dollar figures as of 2002). Id.
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B. What Exactly Do the Patents Cover?
The “claims” of the patent are the most important part of the patent
instrument.181 The claims set forth the rights that are possessed by the
patentee.182 Essentially, the claims define the invention.183 The BRCA1
patent has claims that encompass the nucleotide sequence of the gene, a
method to produce the sequence, and a kit to test for the gene.184 The first
claim of the BRCA1 gene patent is a composition of matter claim that
covers “[a]n isolated DNA coding for a BRCA1 polypeptide, said
polypeptide having the amino acid sequence set forth in SEQ ID NO:2.”185
The BRCA2 patent has similar language.186 SEQ ID NO:2 in the BRCA1
gene lists the amino acids composing the gene; the other claims refer to
various mutations and configurations of the gene.187 Thus, Myriad currently
has a patent on a string of nucleotides, regardless of where they are found,
as long as they exist in the sequence found in the patent.188
In May 2009, the American Civil Liberties Union and the Public Patent
Foundation (collectively “ACLU”) filed suit in the Southern District of
New York challenging the validity of Myriad’s BRCA patents.189 In the
181. SCHECHTER & THOMAS, supra note 28, at 200.
182. Id.
183. Id.; see In re Am. Acad. of Sci. Tech Ctr., 367 F.3d 1359, 1364 (Fed. Cir. 2004)
(holding that during examination, “[patent] claims . . . are to be given their broadest
reasonable interpretation consistent with the specification, and . . . claim language should be
read in light of the specification as it would be interpreted by one of ordinary skill in the
art”).
184. U.S. Patent No. 5,747,282 col.153 l.55 (filed June 7, 1995). The thrust of this
Comment is on composition of matter claims for nucleotide sequences; therefore, the
production and test kit claims are not of concern for this Comment.
185. Id.
186. See U.S. Patent No. 5,837,492 col.167 l.15 (filed Apr. 29, 1996). Claim 1 reads “An
isolated DNA molecule coding for a BRCA2 polypeptide, said DNA molecule comprising a
nucleic acid sequence encoding the amino acid sequence set forth in SEQ ID NO:2.” Id.
187. ’282 Patent col.153 l.55.
188. The patent protection, however, is limited by the isolated and purified standards. See
infra note 203.
189. See ACLU Challenges Patents on Breast Cancer Genes, ACLU (Sept. 22, 2010),
http://www.aclu.org/free-speech_womens-rights/aclu-challenges-patents-breast-cancergenes; see also Complaint at 1, Ass’n. for Molecular Pathology v. U.S. Patent & Trademark
Office, 09 Civ. 4515 (S.D.N.Y. filed May 12, 2009). This Comment was completed,
submitted, and selected for publication before the trial court’s ultimate disposition of the
case. On March 29, 2010, the district court declared the patents invalid because, among other
things, the isolated patent claims covered products of nature. See Ass’n for Molecular
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lawsuit, the ACLU represents approximately 150,000 researchers,
pathologists, and medical professionals190 suing the U.S. Patent and
Trademark Office, Myriad Genetics, and the University of Utah Research
Foundation.191 Interestingly, the ACLU lawsuit is the first to allege a First
Amendment challenge to a gene patent.192 The lawsuit alleges, among other
things, that Myriad’s patents reach into natural human genes, natural gene
mutations, and claims over thoughts or abstract ideas; thus, the patents are
invalid because they represent “products of nature, laws of nature and/or
natural phenomena, and abstract ideas or basic human knowledge or
thought.”193
C. The PTO & Gene Patents
The PTO has fully embraced human genes patents; it has not waited for
congressional approval on the subject.194 However, in light of the increase
of DNA and gene patent applications,195 the PTO amended its utility
standards. In 2001, the PTO adopted new utility guidelines.196 Its purpose
was to ameliorate fears of overly broad DNA patents while concurrently
embracing the “legality” of gene patents.197 The new utility guidelines
require the inventor to disclose a “specific” and “substantial” utility.198
Essentially, with regard to gene patents, the applicant must disclose the
utility of the gene (i.e., what the gene does). In other words, the applicant
cannot merely describe the chemical composition of the DNA sequence;
rather, the applicant must identify a useful purpose of the gene (e.g., a
mutation in the gene that correlates with an increased risk of breast cancer).
The term “specific” according to the PTO means the utility is particular to

Pathology v. U.S. Patent & Trademark Office, 702 F. Supp. 2d 181 (S.D.N.Y. 2010). The
government has appealed the ruling to the Court of Appeals for the Federal Circuit.
190. ACLU, supra note 189.
191. Id.
192. See id.
193. Complaint at 29, Ass’n. for Molecular Pathology v. U.S. Patent & Trademark
Office, 09 Civ. 4515 (S.D.N.Y. filed May 12, 2009).
194. See Utility Examination Guidelines, 66 Fed. Reg. 1092, 1093 (Jan. 5, 2001).
195. The number of applications for human genes increased from 16,000 in 1990 to
33,000 in 2000. M. Scott McBride, Comment, Patentability of Human Genes: Our Patent
System Can Address the Issues Without Modification, 85 MARQ. L. REV 511, 511 (2001).
196. Utility Examination Guidelines, 66 Fed. Reg. 1092, 1092 (Jan. 5, 2001).
197. See id.
198. See id.
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the subject matter claimed.199 Thus, a general statement of diagnostic utility
would not suffice.200 The term “substantial” means a utility that has a “real
world” use.201 The real world use cannot be further research per se, but
rather a practical use.202
The PTO, Myriad, and all other gene patent holders justify the validity of
their patented genes on the premise that the genes are “purified and
isolated.” Thus, they argue that the patented genetic sequences do not occur
in nature. But what exactly does this mean? Essentially, purified and
isolated means that “the gene has been removed from the human body and
the non-coding regions of the gene stripped away.”203
The PTO relies on its own historic practices to justify gene patents. For
example, the PTO proffers Louis Pasteur’s patent on “new” yeast as
justification.204 In addition, the PTO relies heavily on a string of cases
beginning with Merck & Co., Inc. v. Olin Mathieson Chemical Corp.,205
which held that “a new and useful product [that] is the result of processes of
extraction, concentration and purification of natural materials does not
defeat its patentability.”206 Further, In re Bergy207 held that a bacterial
199. Gene Patents and Other Genomic Inventions: Hearing Before the Subcomm. on
Courts and Intellectual Property of the H. Comm. on the Judiciary, 106th Cong. 28 (2000)
(statement of Q. Todd Dickinson, Dir. of the U.S. Patent and Trademark Office).
200. Id.
201. Id.
202. Id.
203. BRCA: Genes & Patents, ACLU (May 27, 2009), http://www.aclu.org/freespeech/brca-genes-and-patents#06. One commentator has compared the phrase “isolated and
purified” to the following analogy:
Compare a field of grass to a strand of DNA. Furthermore, compare a blade of
grass to a gene. While the blade of grass remains in the field, it is in its natural
environment. Similarly, while a gene is attached to its DNA strand, it also is in
its natural environment. Both the blade of grass as well as the gene can be said
to be naturally occurring. When the blade of grass is plucked from its root, it
has been isolated from the rest of the field. Comparably, a gene becomes
isolated when it is purified from its DNA strand.
Stephanie Arcuri, They Call That Natural? An Analysis of the Term “Naturally Occurring”
and the Application of Genes to the Patent Act, 40 VAL. U. L. REV. 743, 745 (2006)
(citations omitted).
204. U.S. Patent No. 141,072 (filed May 3, 1873); see also Utility Examination
Guidelines, 66 Fed. Reg. 1092, 1093 (Jan. 5, 2001).
205. 253 F.2d 156 (4th Cir. 1958).
206. Id. at 163.
207. 596 F.2d 952 (C.C.P.A. 1979), vacated sub nom. Diamond v. Chakrabarty, 444 U.S.
1028 (1980).
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culture is nonetheless patentable because the culture did not exist in nature
in its pure form and could only be produced in a laboratory under certain
circumstances.208 The Federal Circuit has also upheld purified and isolated
DNA patents.209
Finally, with the advent of the new utility standards, the PTO firmly
defends its gene patent stance. Even with the PTO’s new standards,
however, it has been evinced that naturally occurring sequences could still
be patented, so long they are isolated.210 This is why a new standard is
needed.
D. Gene Patents Have Stymied Medical Research
One of the overarching purposes of the products of nature doctrine is to
keep in the storehouse of all men the basic natural principles that are the
bases of other discoveries.211 Thus, the economic purpose behind the
products of nature doctrine, like that of the patent system in general, is to
encourage innovation. By keeping the basics of science free to all, it allows
all to use them in their research. Gene patents, however, have had the
opposite effect.212 Gene patent holders can, among other things, prevent a
doctor from testing a patient’s blood for the gene; stop other scientists from

208.
209.
(noting
genes).
210.

Id. at 987.
See, e.g., Amgen, Inc. v. Chugai Pharm. Co., 927 F.2d 1200, 1206 (Fed. Cir. 1991)
the legal difference between naturally occurring genes and “purified and isolated”

The PTO’s current standard for an isolated and purified gene is:
An isolated and purified DNA molecule that has the same sequence as a
naturally occurring gene is eligible for a patent because (1) an excised gene is
eligible for a patent as a composition of matter or as an article of manufacture
because that DNA molecule does not occur in that isolated form in nature, or
(2) synthetic DNA preparations are eligible for patents because their purified
state is different from the naturally occurring compound.
Utility Examination Guidelines, 66 Fed. Reg. 1092, 1093 (Jan. 5, 2001).
211. See Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 130 (1948); see also
Lori B. Andrews, The Gene Patent Dilemma: Balancing Commercial Incentives With Health
Needs, 2 HOUS. J. HEALTH L. & POL’Y 65, 67-68 (2002).
212. For example, one survey of 2,100 life scientists found that that at least twenty
percent of scientists have delayed publishing research for patenting-related issues. Donald
Willison & Stuart M. MacLeod, Patenting of Genetic Material: Are the Benefits to Society
Being Realized?, 167 CAN. MED. ASS’N J. 259, 260 (2002).
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doing research to improve a genetic test; or preclude others from
developing gene therapies based upon the gene.213
Gene patents have also inhibited research. Variations or mutations in a
gene can cause various diseases.214 Therefore, when one company has a
patent on a gene sequence, it prevents other researchers from discovering
disease-associated mutations.215 One salient example is the search for an
autism-related gene. The search was impeded because American
universities would not share DNA samples with other researchers because
the universities wanted to be able to profit from the discovery and patenting
of the “autism gene.”216
Another salient example, in addition to Myriad and BRCA genes, is
Athena Diagnostics,217 which holds the patent on a gene associated with
Alzheimer’s disease.218 In the past, Athena has not allowed any laboratory,
except its own, to screen for mutations in that gene.219 In another instance,
the PTO granted a patent for a gene related to hemochromatosis (an
autosomal recessive disease), and subsequently thirty percent of surveyed
U.S. laboratories stopped developing genetic tests around that gene.220 The
survey concluded that the issuance of the patent had a measurable effect on
the development and availability of testing services for the gene in the
United States.221 Another study found that twenty-five percent of surveyed
laboratories had stopped or were prevented from providing clinical tests due
to notification of infringement by a gene patent holder.222 Also, gene
213. Lori B. Andrews, Genes and Patent Policy: Rethinking Intellectual Property Rights,
3 NAT. REV. GENETICS 803, 804 (2002).
214. Id.
215. Id.
216. Id.
217. Athena Diagnostics has at various times been associated with and done business as
Athena Neurosciences, Inc. As of February 2000, Athena Neurosciences, Inc. began doing
business as Athena Diognostics. See ATHENA DIAGNOSTICS, http://www.athenadiagnostics.
com/content/about/.
218. See Methods of Screening for Alzheimer’s Disease, U.S. Patent No. 5,508,167 (filed
Apr. 13, 1994); see also 15(3) BIOTECHNOLOGY LAW REPORT 434, 36 (2009).
219. Andrews, supra note 211, at 89.
220. Jon F. Merz, Antigone G. Kriss, Debra G.B. Leonard, & Mildred Cho, Diagnostic
Testing Fails the Test: The Pitfalls of Patents Are Illustrated by Hemochromatosis, 415
NATURE 577, 577 (2002).
221. Id.
222. Mildred Cho, Samantha Illangasekare, Meredith A. Weaver, Debra G.B. Leonard, &
Jon F. Merz, Effects of Patents and Licenses on the Provision of Clinical Genetic Testing
Services, 5 J. MOLECULAR DIAGNOSTICS 3, 5 (2003).
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patents increase the costs associated with genetic research because now
researchers have to pay license fees to patent holders to use the gene
sequences even in the research setting.223 Not only does the patent increase
research costs (due to the required license fees), but it also increases the
costs of the final usable product (e.g., a test for breast cancer) to the
consumer.224 Thus, gene patenting inhibits gene related research and
products.225
IV. SOLUTION
A. The PTO Should Amend Its Utility Requirements and Adopt a Higher
Utility Threshold
The solution to the mounting patentability of human life is to return to
the spirit of the products of nature doctrine—simply, that if the product or
manufacture is found in nature, then it cannot be patented. To comport with
the products of nature doctrine, the proper utility requirements should be
that (1) the claimed utility cannot be substantially similar to the utility
found in the naturally occurring gene and (2) the inventor actually needs to
imbue the utility in the gene, i.e., the utility is not due to natural mutation,
or other natural trait, but rather the genius of the inventor. Some
commentators have proposed that the PTO should only look to the claimed
utility.226 Specifically, if the utility being claimed is substantially similar to
that found in nature, then the patent should not be granted.227 Thus, under
this “substantially similar” approach, if the isolated and purified gene’s
utility is substantially similar to the naturally occurring utility, then the
patent claim would fail the statutory utility guideline.228 While this is a
good start and does seemingly resurrect the products of nature doctrine, this
test is not enough.

223. In one survey, fourteen out of twenty-seven gene patent holders stated they would
require licenses for researchers to study gene mutations in their patented sequences. See
Andrews, supra note 211, at 81.
224. See Merz et al., supra note 220, at 579.
225. In a recent study, sixty-five percent of surveyed laboratories (out of 211 surveyed,
with a sixty-three percent response rate), had been contacted by a patent holder contending
that the laboratory had possibly infringed on a patent. Id.
226. E.g., Sean C. Pippen, Dollars and Lives: Finding Balance in the Patent “Gene
Utility” Doctrine, 12 B.U. J. SCI. & TECH. L. 193, 223 (2006).
227. See id.
228. Id.
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Rather, the proper test to use is the substantially similar framework as
the beginning, but to add an additional layer of analysis asking: who
imbued the utility? Was it the inventor or was it nature? For example, solely
under a substantially similar framework, a gene mutation may still be
patentable. A gene that naturally mutates can exhibit a new utility or
usefulness. This “new” utility, however, is not imbued or instilled by any
man. Rather, it is a latent iteration of the gene’s DNA sequence; thus, it is
still a product of nature.
Therefore, the PTO should adopt a two-pronged approach to gene and
DNA patents and require that (1) the claimed utility is not substantially
similar to that found in nature, and (2) it is the inventor who imbued the
utility through his or her inventiveness. By adopting this proposed twopronged test, the PTO would actually be harmonizing its gene patent stance
with its other standards regarding naturally occurring phenomena.229
The current Manual of Patent Examining Procedures (“MPEP”)
precludes, in theory at least, patenting of naturally occurring phenomena230
except gene patents.231 According to the MPEP, “a thing occurring in
nature, which is substantially unaltered, is not a ‘manufacture.’”232 The
MPEP gives an example of “[a] shrimp with the head and digestive tract
removed is an example [of a naturally occurring article].”233 It is illogical to
assert that the current practice of gene patenting is anything but the
beheaded shrimp in modern technological terms. An isolated and purified
gene is not substantially altered; while it may be different in terms of exact
sequence (due to the exaction of non-coding regions), it nonetheless
operates exactly the same as the naturally occurring gene.234 Thus, the
MPEP is contradictory and expressly disregards the products of nature
doctrine insofar as gene and other DNA patents are concerned.
Therefore, the PTO should once again amend its utility guidelines to
comport with this approach. The current approach, the “specific and
substantial” approach, merely allows a scientist to jot down the DNA’s
naturally occurring utility. With the advent of the Human Genome Project,

229. See PATENT & TRADEMARK OFFICE, MANUAL OF PATENT EXAMINING PROCEDURE
(8th ed. 2006) § 706.03(a)(I)(B) [hereinafter MPEP].
230. See id.
231. For examination guidelines for micro-organisms, the MPEP references § 2105
(citing Diamond v. Chakrabarty, 447 U.S. 303 (1980)).
232. MPEP, supra note 229.
233. Id.
234. Id.
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among other genetic breakthroughs, the obviousness of such future DNA
235
and genetic patents should be questioned as well.
B. The Courts Should Adopt This Two Pronged Test
Even if, however, the PTO does not amend its own utility standards,
courts should still adopt this Comment’s proposed utility standard. The
PTO is merely the “gatekeeper” of the patent system. While the PTO makes
initial and administrative determinations of the patentability of inventions,
the final decision still rests with the courts. Thus, if the PTO were still to
grant patents under its current utility regime, the courts should still hold
most gene patents invalid.
The proposed two-pronged utility standard is founded in case law. The
products of nature doctrine became increasingly important in the industrial
revolution and the scientific breakthroughs occurring in the first few
decades of the twentieth century. In General Electric Co. v. De Forest
236
Radio Co.,
the United States Court of Appeals for the Third Circuit used
Latimer-based reasoning regarding purported tungsten patent claims. In
General Electric, the issue was whether a purported tungsten invention was
a new metal, or varied significantly enough from naturally occurring
tungsten to make it patentable. Coolridge, the inventor of the “new”
tungsten, took naturally occurring tungsten and “purified” it.237 Coolridge
purified the tungsten (or WO3, tungstic oxide) by heating it in a furnace
allowing the metal to free from oxygen, carbon, and other impurities, after
which he submitted the tungsten to other various heating methods.238 After
the heating, the tungsten was “purified,” leaving it with ‘“ductility and high
tensile strength.’”239 It was this “product” that Coolridge claimed, among
others, in his patent. The Court of Appeals affirmed the finding that this
claim was invalid because it was a product of nature.240
The court’s analysis in General Electric embodies a true products of
nature test. While the court was scrutinizing Coolridge’s claim to

235. Granted, this is beyond the scope of the Comment. However, the author does feel
that in light of the modern genetic milieu, “obviousness” will be the forefront of future
lawsuits in this field.
236. 28 F.2d 641 (3d Cir. 1928).
237. Id. at 642.
238. Id.
239. Id.
240. Id. at 643.
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241
“substantially pure tungsten,” it asked “who created pure tungsten.” Of
course, the court found that Coolridge did not create pure tungsten; rather, it
existed in nature for centuries. The court stated that “[t]he fact that no one
before Coolidge found it there does not negat[e] its origin or existence.” 242
The court focused on the creator of the product. Next, the court analyzed
243
his claim to “having ductility and high tensile strength.” Once again, the
court asked whether Coolridge imbued those qualities to his “pure
tungsten.” And again, the court found in the negative: Coolridge did not
imbue the special characteristics of pure tungsten; rather, they existed
244
naturally in tungsten the entire time. Therefore, the court found that this
claim to “substantially pure tungsten” was over a product of nature and thus
unpatentable.245
The importance of General Electric, however, reaches beyond the Third
Circuit. In In re Marden, 246 the Court of Customs and Patent Appeals247
adopted the Third Circuit’s rationale in General Electric. In Marden, the
inventor was seeking patent protection of claims to “ductile uranium.”248
The court found the reasoning in General Electric to be the standard by
which to gauge the products of nature analysis. In Marden, the court held
that the “inventor” is not entitled to patent “the same, or upon any of the
inherent natural qualities of [uranium].”249 The importance of Marden was
that the Court of Customs and Patent Appeals, the predecessor to the
current Court of Appeals for the Federal Circuit, adopted the General
Electric standard for products of nature; the General Electric standard
being that the court should examine: (1) who created the product and (2)
who imbued the special characteristics meriting patent protection.250
This analysis has its basis in the classical notion of the products of nature
251
doctrine set forth in Latimer. In Latimer, the Patent Commissioner held
that Latimer was not entitled to patent protection because he ascertained the

241. Id.
242. Id.
243. Id.
244. Id.
245. Id.
246. 47 F.2d 957, 957 (C.C.P.A. 1931).
247. The Court of Customs and Patent Appeals no longer exists and was replaced by the
Court of Appeals for the Federal Circuit.
248. Marden, 47 F.2d at 957.
249. Id.
250. Gen. Elec. Co. v. De Forest Radio Co., 28 F.2d 641, 643 (3d Cir. 1928).
251. Ex parte Latimer, 1889 Dec. Pat. Comm’r. 123, 125 (1889).
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252
The Commissioner likened
character or quality of the composition.
Latimer’s purported claim to a discoverer who finds a new gem in the earth
would be entitled to all like gems subsequently found.253 Granting a patent
on the plant fiber would be akin to allowing patent protection to “one who
gathers the pebbles along the seashore, where the forces of nature have
254
The Commissioner, however, did articulate that if
placed them.”
Latimer’s process had in some way imbued the fiber with something new or
different, then it would qualify as a product or manufacture under the patent
255
act.
Economic pressures in granting patents are not new. In Latimer, the
Commissioner was plagued by pressures to grant the patent.256 The
Commissioner lamented that “[t]he alleged invention is unquestionably
very valuable . . . [and] of immense benefit . . . . [but] the invention resides,
I am compelled to say, exclusively in the process and not at all in the
257
product.” Therefore, as early as Latimer, the patent office recognized that
the inventor had to do something special, not the claimed product, even if
the invention was valuable.
Similarly, in Chakrabarty, the genesis of DNA patents, the Supreme
Court went to great lengths to show the novelty of Chakrabarty’s bacteria.
The Court pointed to the fact that the bacterium is “a nonnaturally occurring
manufacture or composition of matter—a product of human ingenuity
258
‘having a distinctive name, character [and] use.’” Furthermore, the Court
emphasized that Chakrabarty’s bacterium “[has] markedly different
characteristics from any found in nature and . . . is not nature’s handiwork,
but his own.”259 Thus, the critical reason for holding the bacteria patentable
was its uniqueness insofar as it did not exist in nature, it could not be
created in nature, and it had a property not found in nature. Therefore, in
Chakrabarty the analysis focused on that it was Chakrabarty’s ingenuity

252. Id. (“[B]ecause the mere ascertaining of the character or quality of trees that grow in
the forest and the construction of the woody fiber and tissue of which they are composed is
not a patentable invention, recognized by the statute.”).
253. Id.
254. Id. at 126.
255. Id.
256. Id. at 127.
257. Id.
258. Diamond v. Chakrabarty, 447 U.S. 303, 309-10 (1980) (quoting Hartranft v.
Wiegmann, 121 U.S. 609, 615 (1887)).
259. Id. at 310.
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that imbued the bacteria with its properties (adding the two distinct
bacterium together), not any handiwork of nature.
This Comment’s proposed utility test comports with Supreme Court
precedent. The Court applied a similar test in Funk Brothers Seed Co. v.
260
261
Kalo Inoculant Co., at the height of the products of nature doctrine. In
Funk Brothers, the Court reviewed a Court of Appeals decision that
262
affirmed the validity of a product patent. The patent claimed a mixed
culture of Rhizobia (a bacteria) capable of inoculating the seeds of plants
that otherwise could not be inoculated efficiently.263 The inventor, Bond,
discovered that by mixing certain strains of different species of plants he
could bypass some of the biological inhibitors.264 The key to Bond’s
265
invention was the use of “inhibitors.” The Court reversed the Court of
Appeals and held that the patent was invalid.266
The Court held that Bond’s invention was a product of nature and thus
267
First, the Court examined whether Bond created the
unpatentable.
268
utility. The Court stated that the sought after quality (inhibition or noninhibition) is the work of nature.269 According to the Court, “Those
qualities are of course not patentable. For patents cannot issue for the
discovery of the phenomena of nature.”270 The crux of this rationale was
that the bacteria’s qualities “are part of the storehouse of knowledge of all
men.”271 Manifestations of the laws of nature (e.g., a bacteria’s qualities in
Funk) are “free to all men and reserved exclusively to none.”272 The Court
acknowledged the incredible commercial value of Bond’s bacteria, but

260. 333 U.S. 127 (1948).
261. Donna M. Gitter, International Conflicts Over Patenting Human DNA Sequences in
the United States and the European Union, 76 N.Y.U. L. REV. 1623, 1640 (2001).
262. Funk Bros. Seed Co., 333 U.S. at 128.
263. Id. at 128-130.
264. Id. at 130.
265. Id.
266. Id. at 132.
267. Id. at 130.
268. Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 130 (1948) (noting that
the patent holder did not “create a state of inhibition or of non-inhibition in the bacteria”).
269. Id.
270. Id.
271. Id.
272. Id.
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because it was the “discovery of some of the handiwork of nature,” it was
273
not patentable, regardless of value.
The Funk holding does not preclude all biotechnology patents, nor does
this Comment’s test; but, what they seek to accomplish is harmonization
between patentable subject matter and the purpose of the patent system. The
Funk Court did recognize that there are circumstances where
biotechnological patents are completely valid. The Court stated in Funk, “If
there is to be invention from such a discovery, it must come from the
application of the law of nature to a new and useful end.”274 The Court
found that Bond’s bacteria did not acquire a different use from the naturally
occurring function.275 Next, the Court found that the bacteria performed in
276
In sum, Bond’s new and improved bacteria did not
their natural way.
improve their natural functioning and served the ends or purposes that
nature originally intended.277
Detractors of this new utility test may assert that it would completely
nullify thousands of biotechnology patents, but this is not true. Under this
Comment’s proposed two-pronged test, all of the discussed cases would
have the same outcome. While their holdings would be the same, the
proposed two-pronged test would invalidate patents that should have never
received patent protection and concomitantly harmonize the patent system
with its purpose of encouraging ingenuity but keeping products of nature in
the “storehouse of all men.”
In Latimer, the patent would still be denied. First, the utility was
substantially similar to that found in nature (the strength of the fibers),278
and second, as the Patent Commissioner pointed out, Latimer did not imbue
the strings with his inventiveness.279 Rather, Latimer merely identified the
naturally imbued properties of the fibers. In Chakrabarty, the patent would
still have been deemed valid. First, Chakrabarty was neither patenting any
product with a natural analogue, nor was that specific utility found in nature
(e.g., an oil-consuming bacteria). Second, it was the inventiveness of
273. Id. at 131.
274. Id. at 130 (emphasis added).
275. Id. at 131. In other words, the bacteria was still used to inoculate plants—exactly
what it was being used for before Bond’s improvement.
276. Id. This would be analogous to the “substantially similar” test espoused by this
Comment.
277. Id. The Court expressly focused on whether the invention acted independent of what
it would in nature due to the effort of the patentee.
278. Ex parte Latimer, 1889 Dec. Pat. Comm’r. 123, 123 (1889).
279. Id.
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Chakrabarty that imbued the bacteria with their utility. In other words, it
was the combination of products, due to Chakrabarty’s genius, that gave the
bacteria their utility, not a naturally occurring phenomenon. In Funk, the
patent would still be invalid. The Court held that the function was too
similar to its naturally occurring function, and that the inventor did not
imbue the invention with the utility.280 Thus, the proposed two-pronged test
would keep the hallmarks of biotechnology cases unperturbed and restore
the integrity of the patent system.
C. Ethics Regulations Should Be Adopted to Invalidate Human Gene
Patents
Another avenue to invalidate human gene patents is ethics regulations.
Human life is special and unique.281 Human gene patenting is not just a
legal issue: it is a legal, economic, and even a religious issue.282 Human life
is a gift from God.283 Thus, life and the human body are not just the sum of
chemical formulas, but rather a special divine work. Therefore, the
patenting of anything that can amount to human life should be prohibited.284
Also, by allowing a select few to have the right to preclude others from
280. Chakrabarty, 447 U.S. at 306
281. See Genesis 1:26 (NASB) (God said, “Let Us make man in Our image, according to
Our likeness; and let them rule over the fish of the sea and over the birds of the sky and over
the cattle and over all the earth, and over every creeping thing that creeps on the earth.”);
Job 10:12 (NASB) (“You have granted me life and lovingkindness; And Your care has
preserved my spirit.”); Jeremiah 1:4-5a (NASB) (“Now the word of the LORD came to me
saying, ‘Before I formed you in the womb I knew you, And before you were born I
consecrated you; I have appointed you a prophet to the nations.’”); 1 Corinthians 6:19-20
(NASB) (“Or do you not know that your body is a temple of the Holy Spirit who is in you,
whom you have from God, and that you are not your own? For you have been bought with a
price: therefore glorify God in your body.”).
282. See Mark J. Hanson, Religious Voices in Biotechnology: The Case of Gene
Patenting, in CLAIMING POWER OVER LIFE 73 (Mark J. Hanson ed., 2001). The ethical debate
around gene patents encompasses not only the law, but also a clash of worldviews. Id. A
worldview is a set of beliefs and ideas that influences how one evaluates the world. Id.
Under a Christian worldview, the patenting of isolated genes that are based upon naturally
occurring human genes presents a seeming infringement upon God’s handiwork. But for the
person who believes that humans are the end result of eons of random chemical mutations, it
makes complete sense that human DNA is a chemical compound like any other.
283. See Genesis 1:26; Job 10:12; Jeremiah 1:4-5a; 1 Corinthians 6:19-20.
284. One commentator, however, has suggested that a Roe v. Wade framework should be
used to determine whether genes qualify as a living entity. See M. Scott McBride,
Patentability of Human Genes: Our Patent System Can Address the Issues Without
Modification, 85 MARQ. L. REV 511, 529 (2001).
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using certain DNA sequences for research and other societal benefit is
morally wrong and reprehensible.285
Allowing the continued patenting of human genes may even be the first
step to human “commodification.”286 In the broad sense of the word,
commodification occurs when one “conceives of human attributes
(properties of a person) as fungible owned objects (the property of the
person).”287 Religious commentators equate gene patenting with wrongfully
transferring ownership of the creation from the Creator (God) to the
creation (man).288 This commodification manifests in attempts to patent
specific gene or cell lines of people with abnormal immunity or other
special genetic traits.289 Some individuals have even applied for patents on
their own entire genome.290 The PTO, however, has shrugged off any
attempts to use morals or ethics as a roadblock to gene patenting.291

285. President Bill Clinton and British Prime Minister Tony Blair issued a joint statement
concerning gene patents stating, “[R]aw fundamental data on the human genome, including
the human DNA sequence and its variations, should be made freely available to scientists
everywhere.” Gitter, supra note 261, at 1629.
286. See Linda J. Demaine & Aaron Xavier Fellmeth, Reinventing the Double Helix: A
Novel and Nonobvious Reconceptualization of the Biotechnology Patent, 55 STAN. L. REV.
303, 440 (2002) (noting that Kant’s Categorical Imperative posits that humans should not be
used for one’s own end).
287. MARGARET JANE RADIN, CONTESTED COMMODITIES 13 (1996).
288. For example, one commentator has stated:
Human beings are pre-owned. We belong to the sovereign Creator. We are,
therefore, not to be killed without adequate justification (e.g., in self-defense)
nor are we, or our body parts, to be bought and sold in the marketplace. Yet the
patenting of human genetic material attempts to wrest ownership from God and
commodifies human biological materials and, potentially, human beings
themselves. Admittedly, a single human gene or a cell line is not a human
being; but a human gene or cell line is undeniably human and warrants
different treatment than all nonhuman genes or cell lines. The image of God
pervades human life in all of its parts. Furthermore, the right to own one part of
a human being is ceteris paribus the right to own all the parts of a human
being. This right must not be transferred from the Creator to the creature.
Richard D. Lane & C. Ben Mitchell, Patenting Life: No, 63 FIRST THINGS (May 1996),
available at http://www.firstthings.com/article/2007/10/005-patenting-life-no-4. But see Ted
Peters, Patenting Life: Yes, 63 FIRST THINGS (May 1996), available at
http://www.firstthings.com/article/2007/10/004-patenting-life-yes-24.
289. See supra note 153 (discussing the patenting of the gene sequences of Hawaiian and
Papua New Guinea people).
290. See Lori B. Andrews, The Gene Patent Dilemma: Balancing Commercial Incentives
With Health Needs, 2 HOUS. J. HEALTH L. & POL’Y 65, 65 (2002). In 2000, Donna
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Ethics regulations regarding intellectual property are not uncommon.
The Agreement on Trade-Related Aspects of Intellectual Property Rights
(TRIPS Agreement), an international intellectual property agreement,
allows member countries to exclude from TRIPS protection patents that are
contrary to public order or morality.292 The TRIPS Agreement expressly
allows exceptions to protect human life.293 In addition, the European Patent
Organization and its thirty-four member countries have the Biotechnology
Directive.294 The Biotechnology Directive has a morality exception that
precludes any intellectual property protection that contravenes public policy
or morality.295 The Biotechnology Directive also expressly precludes the
patenting of certain biotechnology inventions or processes, for example, the
cloning of human life.296

Rawlinson MacLean filed a patent application with the British Patent Office entitled
“Myself” wherein she purported to patent her own genetic sequence. Id.
291. See Utility Examination Guidelines, 66 Fed. Reg. 1092, 1093 (Jan. 5, 2001)
(rejecting express proposals that argued genes are “at the core of what it means to be
human”).
292. Agreement on Trade-Related Aspects of Intellectual Property Rights art. 27, ¶ 2,
Apr. 15, 1994, 1869 U.N.T.S. 299 [hereinafter TRIPS].
293. Id. While TRIPS does not expressly preclude “gene patents,” it does contain
language allowing for preclusion of patents to protect human life or morals; this language
arguably allows for gene patent preclusion.
294. Council Directive 98/44, art.1, 1998 O.J. (L 213) 1, 2 (EC) [hereinafter
Biotechnology Directive]; see Erin Bryan, Gene Protection: How Much Is Too Much?, 9 J.
HIGH TECH L. 52, 56-57 (2009); see also Franz-Josef Zimmer & Svenja Sethmann, Act
Implementing the Directive on the Legal Protection of Biotechnological Inventions in
Germany, 24 BIOTECH. L. REP. 561 (2005).
295. See Bryan, supra note 294, at 58. The Biotechnology Directive provides, among
other things, “Inventions shall be considered unpatentable where their commercial
exploitation would be contrary to ordre public or morality; however, exploitation shall not
be deemed to be so contrary merely because it is prohibited by law or regulation.”
Biotechnology Directive, supra note 294, art. 6, ¶ 1.
296. Biotechnology Directive, supra note 294. In fact, the following are precluded under
the Biotechnology Directive:
On the basis of paragraph 1, the following, in particular, shall be considered
unpatentable: (a) processes for cloning human beings; (b) processes for
modifying the germ line genetic identity of human beings; (c) uses of human
embryos for industrial or commercial purposes; (d) processes for modifying the
genetic identity of animals which are likely to cause them suffering without any
substantial medical benefit to man or animal, and also animals resulting from
such processes.
Id. at art. 6, ¶ 2.
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The German Patent Act, however, only allows for partial protection of
human gene sequences.297 Under German law, gene patent protection is
only given for functions as compared to DNA sequences.298 Such restrained
protection is different from the American and other European patent
systems. The American system requires disclosure of a function to grant
protection to the entire DNA sequence, including any other useable
functions; whereas, the German system would only offer protection for the
identified function.299 Germany reasoned that the absolute protection of
human DNA sequences should not be granted.300 The German approach still
allows others to use the gene sequences so long as it is not for the function
in the patent; the PTO has expressly rejected this compromise.301
There have been proposals, albeit unsuccessful ones, to pass similar
legislation in the United States.302 In 2007, Congressman Xavier Becarra
(D-CA)303 introduced “The Genomic Research and Accessibility Act.”304
The Act was quite simple: it sought to amend Title 35 of the U.S. Code and
provided, “Notwithstanding any other provision of law, no patent may be
obtained for a nucleotide sequence, or its functions or correlations, or the
naturally occurring products it specifies.”305 Congressman Becarra
introduced and referred the Bill to both the House Judiciary Committee and
the House Judiciary Subcommittee on Courts, the Internet, and Intellectual
Property. The Bill, however, has not made any progress at becoming law.
D. Congress Should Enact a Human Gene Patent Fair-Use Exemption
If the courts306 and the PTO are unwilling to honor the products of nature
doctrine, Congress can still ameliorate the threats of gene patents to
297. See Bryan, supra note 294, at 60; see also Zimmer & Sethmann, supra note 294.
298. See Bryan, supra note 294, at 60. While Germany has stricter (more restrictive)
DNA patent laws, it cannot enforce these laws against European Patent Office granted
patents. Id.
299. Id.
300. Id.
301. See Utility Examination Guidelines, 66 Fed. Reg. 1092, 1095 (Jan. 5, 2001).
302. See Roger D. Klein, Gene Patents and Genetic Testing in the United States, 25
NATURE BIOTECHNOLOGY 989, 989 (2007).
303. The bill was also co-sponsored by Congressmen Weldon (R-FL), Stark (D-CA),
Carson (D-IN), Shea-Porter (D-NH), Degette (D-CO), and Sanchez (D-CA).
304. H.R. 977, 110th Cong. (2007).
305. Id. § 2(a).
306. There have been courts that have recognized, at least in theory, the promise of a
patent fair use exemption. See Whittmore v. Cutter, 29 F. Cas. 1120, 1121 (C.C.D. Mass.
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research by creating fair-use type exemptions307 for research.308 Attempts to
enact such an exemption thus far have failed. In 1990, Congress proposed
the “Research, Experimentation, and Competitiveness Act.” 309 The Act
provided that “It shall not be an act of infringement to make or use a
patented invention solely for research or experimentation purposes unless
the patented invention has a primary purpose of research or
experimentation.”310 Again in 2002, Congress tried to create a specific
genetic sequence information exemption.311 This Act would have provided,
“It shall not be an act of infringement for any individual or entity to use any
patent for or patented use of genetic sequence information for purposes of
research.”312 The most recent attempt, in 2007, would simply preclude all
patents for nucleotide sequences.313 Regardless of the attempts to provide
fair-use exemptions, such attempts would not be necessary if the products
of nature doctrine was properly understood and applied because such
patents covering the utility of naturally occurring genes (and DNA
sequences) would be invalid.

1813) (“[I]t could never have been the intention of the legislature to punish a man, who
constructed such a machine merely for philosophical experiments, or for the purpose of
ascertaining the sufficiency of the machine to produce its described effects.”); see also
Poppenhusen v. Falke, 19 F. Cas. 1048, 1049 (C.C.S.D.N.Y. 1861) (holding that an
“experiment with a patented article for the sole purpose of gratifying a philosophical taste, or
curiosity, or for mere amusement is not an infringement of the rights of the patentee”).
However, the purported judicially created experimentation fair use defense has not been
effective in practice. See Rebecca S. Eisenberg, Patents and the Progress of Science:
Exclusive Rights and Experimental Use, 56 U. CHI. L. REV. 1017, 1023 (1989).
307. In copyright law, there is a “fair use” exemption from copyright infringement. If a
copyrighted work is used for certain purposes (such as “criticism, comment, news reporting,
teaching . . . scholarship or research”), the use is not an infringement of a copyright. 17
U.S.C. § 107 (2006).
308. Without such a fair use exemption, even “innocent” infringement is still prohibited
under patent law. See Eisenberg, supra note 306. Thus, if there are two research laboratories,
and one has a gene patent and the other stumbles upon the isolated sequence and starts to
develop innovative products around the gene, the former laboratory can preclude the latter
from development. See id. at 1021.
309. H.R. 5598, 101st Cong. § 402 (1990) (proposing to amend 35 U.S.C. § 271(j)).
310. Id.
311. Genomic Research and Diagnostic Accessibility Act of 2002, H.R. 3967, 107th
Cong. § 2 (2002) (proposing to amend 35 U.S.C. § 271(j)(1)).
312. Id.
313. Genomic Research and Accessibility Act, H.R. 977, 110th Cong. § 2 (2007)
(proposing to amend 35 U.S.C. § 106).
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E. Bayh-Dole’s “March-In” Rights Are Neither a Viable Nor Realistic
Solution
The Bayh-Dole Act314 allows certain entities, including non-profit
organizations and universities, to retain ownership over patents that arise
from the use of federal funds.315 Before Bayh-Dole, if federal funds were
used to create a patented invention, the federal agency doling out the funds
retained ownership over the patent.316 In theory, the purpose of the BayhDole Act is to improve technology transfers by incentivizing qualified
entities to create technology by reaping the royalties and license fees.317
One caveat of the Act, however, is the “march-in” rights provision.318
Under march-in rights, if the patent holder fails to commercialize the
invention, or if the invention is needed for “health or safety needs,” the
federal agency can “march-in” and grant a license to a petitioner.319 Thus,
march-in rights are purported to keep the balance between the monopoly
granted under the patent and the idea that public funds should be used for
the public good.320 Therefore, if a gene patent holder was at least partially
federally-funded, the government could “march-in” and grant others
licenses to use the gene sequences.321
314. 35 U.S.C. §§ 200–212 (2006) (Patent and Trademark Act Amendments of 1980,
also known as the Bayh-Dole Act).
315. 35 U.S.C. § 202 (2006). See generally Mary Eberle, March-In Rights Under the
Bayh-Dole Act, 3 MARQ. INTELL. PROP. L. REV. 155 (1999).
316. See Eberle, supra note 315, at 155-56.
317. Id.
318. 35 U.S.C. § 203 (2006).
319. See id.
320. See 35 U.S.C. § 200 (2006).
321. The government would have to find that at least one of the four criteria in 35 U.S.C.
§ 203 is been satisfied. The criteria in § 203 are:
(1) action is necessary because the contractor or assignee has not taken, or is
not expected to take within a reasonable time, effective steps to achieve
practical application of the subject invention in such field of use;
(2) action is necessary to alleviate health or safety needs which are not
reasonably satisfied by the contractor, assignee, or their licensees;
(3) action is necessary to meet requirements for public use specified by Federal
regulations and such requirements are not reasonably satisfied by the
contractor, assignee, or licensees; or
(4) action is necessary because the agreement required by section 204 has not
been obtained or waived or because a licensee of the exclusive right to use or
sell any subject invention in the United States is in breach of its agreement
obtained pursuant to section 204.
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A recent study found that when universities and research institutes, who
hold many gene patents, regularly enforce their patent rights, laboratories
are discouraged from performing further research and experimentation.322
Of those universities and research institutes, more than half of the gene
patents were, at least in part, federally-funded.323 Despite the seeming
promise of march-in rights, they have been unsuccessful in application.324
In fact, there has not yet been one case of the United States exercising its
Bayh-Dole march-in rights.325 Thus, it appears as though the public’s right
to benefit from public research funds is doubtful.326 Therefore, arguments
contending that Bayh-Dole is sufficient to protect the rights of the people to
access important research, e.g., a gene sequence for detecting breast cancer,
are tenuous at best.
F. The Two-Pronged Utility Solution Proposed Does Not Invalidate Gene
Patents Per Se
This Comment does not argue that all DNA or gene patents should be
invalid per se. Rather, the purposes of the proposed two-pronged utility test
are three-fold: (1) to restore the products of nature doctrine; (2) to keep
important biological information in the storehouse of all men; and (3) to
respect the sanctity of human life. There are instances under the twopronged framework where many DNA and gene patents could still be
patented, and rightly so, and yet still conform to the proposed test and the
purpose of the patent system. For instance, suppose an inventor takes Gene
A and splices some of the DNA with Gene B to create Gene C. Now,
assuming arguendo that if Gene C has no natural analogue and has no
utility substantially similar to a naturally occurring gene, Gene C would be
patentable. First, Gene C passes the substantial similarity prong, and
second, it also passes prong two insofar as the inventor through his creative
genius of splicing the genes together actually imbued the utility in Gene C.
This is essentially what the Supreme Court approved in Chakrabarty.

35 U.S.C. § 203 (2006)
322. Mildred K. Cho, Samantha Illangasekare, Meredith A. Weaver, Debra G. B.
Leonard & Jon F. Merz, Effects of Patents and Licenses on the Provision of Clinical Genetic
Testing Services, 5 J. MOLECULAR DIAGNOSTICS 3, 6 (2003).
323. See id.
324. See id.
325. Eberle, supra note 315, at 160.
326. Id.
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Also, neither this Comment nor its two-pronged test would invalidate
gene-testing products. One of the main aims of genetic research is
developing tests that detect the presence of certain genes and their
mutations. This Comment does not foreclose the patenting of these tests.
An inventor, for example Myriad, could still properly have a product patent
on its gene-detecting test, but not on the underlying gene itself. This is a
reasonable approach that still offers the incentive for genetic research, yet
keeps the actual purified and isolated gene in the public domain for research
and other reasons.327 Thus, new biotechnological inventions such as
medicine or DNA therapies could still be properly patentable, and this test
would not implode the biotechnological sector.
V. CONCLUSION
In conclusion, the PTO should amend its gene utility requirements to
require that (1) the claimed utility is not substantially similar to that found
in nature, and (2) it is the inventor who imbued the utility through his or her
work. Even if the PTO did not adopt this standard, courts should still use
this test to invalidate certain gene patents. This test would work to alleviate
the many pressures and conflicts surrounding the gene patent debate; would
align the utility requirement with decades of case law; and would still
support the holdings of the classic cases of Latimer, Funk, and
Chakrabarty. This test would restore the products of nature doctrine, keep
important biological information in the storehouse of all men, and respect
the sanctity of human life. Without the adoption of this test, many women
like Lisbeth Ceriani will be foreclosed from the medical treatment they
desperately need.

327. The position of allowing the validity of the product claim for detection kits, among
others, but not the underlying gene flows naturally from this Comment’s approach.

